SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 9th, 2024 • Alzamend Neuro, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is entered into and effective as of May 8, 2024 (the “Execution Date”), by and between Alzamend Neuro, Inc., a Delaware corporation (the “Company”) and Orchid Finance LLC, a Nevada limited liability company (including its designees, successors and assigns, the “Purchaser”).
ContractAlzamend Neuro, Inc. • May 9th, 2024 • Pharmaceutical preparations
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 9th, 2024 • Alzamend Neuro, Inc. • Pharmaceutical preparations
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and the Purchaser (the “Purchase Agreement”).
